8:30 am Registration & Coffee

8:55 am Chair’s Opening Remarks

Remaining Gaps Within Atopic Dermatitis & Psoriasis: Opportunities for Further Improvement

9:00 am Challenges in Dermatological Drug Development for Chronic Diseases: How to Improve, What Remains to be Done?


  • Reviewing the current challenges in conduction clinical development in Dermatology example within AD and Psoriasis
  • Discussing the importance of clinical insights gathering and data gap analysis, what once was enough no longer is enough
  • Looking forward, what are the study design limitations and how do we approach these?

9:30 am Identifying New Targets to Sustain Innovation Within Atopic Dermatitis

  • Hyun Kim Vice President - Clinical Development & Head of Clinical Operations, AOBiome


  • Current review of existing approaches in AD
  • Discussing AOBiomes novel approach
  • Looking forward in development approaches

Identifying Skin Screening & Imaging Technologies to Improve Patient Identification, Diagnosis & Disease Progression Tracking

10:00 am AI Assisted Objective Skin Imaging & Analysis of Skin Diseases & Drug Effects in Clinical Trials

  • Harald Schnidar Chief Executive Officer & President, Scarletred Holding Gmbh


  • Standardised high quality mobile skin imaging
  • Smart skin imaging data and objective image analysis
  • Machine learning and AI powered decision support in trials and new digital skin biomarker and endpoints in HS and beyond

10:30 am Speed Networking


This session is the perfect opportunity to get face-to-face time with the key opinion leaders in the dermatology field. Establish meaningful business relationships to build upon for the rest of the conference and gain individual insight into the pioneering research and therapeutic development.

11:15 am Morning Break

11:30 am Utilisation of Novel Digital Health Technologies to Improve the Efficiency of Clinical Development Programs & Patient Satisfaction

  • Sreekumar Pillai Executive Director - Immunology & Clinical Development, Eli Lilly


  • Using imaging technology to identify and diagnose patients
  • Using MedTech to quantitatively measure subjective measures such as itch
  • Measuring and improving patient compliance with interactive applications to track disease

12:00 pm Automating Complex Diagnostics & Translational Biomarker Assessments


  • Molecular diagnostics at the point-of-need
  • Differentiating Psoriasis and Atopic Dermatitis for clinical trials
  • Inflammatory marker panels for drug development

12:10 pm Integrated Therapeutic Solutions for Drug Research & Development in Dermatology: Concept to Clinic

  • Ekkehard May Head of Cross Indication Research Department, Nuvisan


  • The most rewarding and challenging milestone in pharma R&D is a successful proof-of-concept (PoC) in humans
  • Optimized preclinical strategy for the targeted indication is a crucial element that de-risks the PoCs
  • An integrated therapeutic solution approach increases project efficiency while providing expertise and support from early-stage compound identification to drug product development. Key elements include understanding target biology and mode-of-action, selection of optimal indication, in vitro and in vivo preclinical data, formulation development and clinical study supply and conduct

12:20 pm Implementing a Patient Centric Approach to Optimise Retention & Compliance

  • Lars Rosendal Vice President, Global Clinical Operations, LEO Pharma


  • Increasing patient compliance with modern technology
  • Using technology to assess patient decentralised engagement in clinical trials
  • Looking at the implication of decentralised clinical trials in dermatology

12:50 pm Lunch Break

Mitigating Risk & Maximising Success by Enhancing Preclinical Models & Improving Topical Product Development

2:00 pm Roundtable Discussion:Overcoming the Unreliability of Preclinical Models of Dermatological Diseases to Reduce Efficacy Data Failure


This interactive session gives you the opportunity to be part of the discussion, share ideas and learn from your peers. Choose the table most relevant to you, and get ready to be part of this conversation:

  • Evaluating Current Preclinical Models Ability to Predict PK/PD In Vivo
  • Discussing the Future Applications of Teledermatology

2:30 pm The Benefits of Rational Design in Topical Formulation Development


  • Topical formulations are often complex, but the underlying physics and chemistry can be generally understood
  • Rational design of formulations and analytical methods enables efficient development and de-risking 
  • Judgement and decision making are critical in topical formulation development 

2:40 pm Harnessing Oligonucleotides in Topical Therapy for Atopic Dermatitis


  • Discovery of an immune checkpoint inducer
  • Proof of concept study in dogs suffering Atopic Dermatitis
  • New steps in development of a new kind of treatment 

3:10 pm Developing Topical Products with Confidence: Mitigating Risk & Maximising Success

  • Florencia Guidali Head Of Formulation Development and Lab Opearations, MedPharm Holdings


  • Preformulation and formulation development
  • Testing performance to de-risk your programs
  • The crucial role of process development

3:20 pm Afternoon Break

3:50 pm Overcoming Partial Recapitulation of Pemphigus and Other Underserved Autoimmune Blistering Diseases in Preclinical Models

  • Carlo Pincelli Professor of dermatology and Chief Medical Officer PinCell srl, PinCell


  • Successful use of in vitro, ex-vivo and in vivo models to close the gap for the development of new treatments
  • Utilising humanised transgenic mouse models in pemphigus
  • Evidence for a safe/efficacious targeting of human Fas ligand in vivo

4:10 pm Clinically Predictive Assays to Dissect the Potential of a Drug or a Target for Dermatological Disorders

  • Marta Bertolini Chief Executive & Scientific Officer, Monasterium Laboratory


  • Discussing key aims for pre-clinical research
  • Presenting in-vitro, ex-vivo, and in vivo models
  • Understanding the advantage of customised approaches

4:25 pm Overviewing the Challenges Preventing Progression in Rare Dermatological Diseases


  • Reviewing indications where genetics are known and why these lack therapeutic options
  • What’s next for conditions where underlying pathologies aren’t known?
  • How Palvella have been tackling these issues to treat hyperkeratotic skin diseases

4:55 pm Chair’s Closing Remarks

5:00 pm End of Day 1